SHOC2-RAS PPI-IN-1
SHOC2-RAS PPI-IN-1 (compound 6) is a non-covalent competitive inhibitor targeting the interaction between SHOC2 and RAS proteins. SHOC2-RAS PPI-IN-1 has an IC50 of 0.048 μM and a KD of 0.065 μM for NRASQ61R. SHOC2-RAS PPI-IN-1 can inhibit the activity of the SMP phosphatase complex, leading to increased CRAFS259 phosphorylation levels, thereby blocking the MAPK signaling pathway (such as reducing the levels of pMEK and pERK), inducing tumor cell cycle arrest and apoptosis. SHOC2-RAS PPI-IN-1 can be used for targeted research on malignant tumors such as melanoma and colorectal cancer with NRASQ61R mutations[1].
Product Specifications
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Apoptosis; Ras
Related Pathways
Apoptosis; GPCR/G Protein; MAPK/ERK Pathway
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Purity
99.50
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O=C(O)C(C)(C)[C@H](NC(CC1=CC=CC(I)=C1)=O)C2=CC=C(OC(N3)=O)C3=C2
Molecular Formula
C20H19IN2O5
Molecular Weight
494.28
Precautions
H302, H315, H319, H335
References & Citations
[1]Hauseman ZJ, et al. Targeting the SHOC2-RAS interaction in RAS-mutant cancers. Nature. 2025 Jun;642 (8066) :232-241.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
E-Cadherin / CD324 (Intercellular Junction Marker) (4A2), CF405S conjugate, 0.1mg/mL
CD10 (CB-CALLA), CF640R conjugate, 0.1mg/mL
